

## APPENDIX 1

# HIV Antiretroviral and Opportunistic Infection Medications

FDA-Approved Antiretroviral Medications	
Generic Name	Brand Name
<b>CYP34A Inhibitors (Pharmacokinetic Boosters)</b>	
cobicistat	Tybost
<b>Multi-Class Combination Products</b>	
abacavir/lamivudine, dolutegravir	Triumeq
bictegravir/emtricitabine/tenofovir alafenamide	Biktarvy
cobicistat, elvitegravir, emtricitabine, tenofovir alafenamide	Genvoya
cobicistat, elvitegravir, emtricitabine, and tenofovir disoproxil fumarate	Stribild
dolutegravir/rilpivirine	Juluca
efavirenz, emtricitabine, and tenofovir disoproxil fumarate	Atripla
emtricitabine, rilpivirine, and tenofovir alafenamide	Odefsey
emtricitabine, rilpivirine, and tenofovir disoproxil fumarate	Complera
<b>NRTIs</b>	
abacavir sulfate, ABC	Ziagen
abacavir, zidovudine, and lamivudine	Trizivir
abacavir/lamivudine	Epzicom
didanosine	Videx EC
didanosine, dideoxyinosine, ddI	Videx
emtricitabine, FTC	Emtriva
emtricitabine, tenofovir alafenamide	Descovy
lamivudine and zidovudine	Combivir
lamivudine, 3TC	Epivir
stavudine, d4T	Zerit
tenofovir, disoproxil fumarate, TDF	Viread
tenofovir disoproxil fumarate and emtricitabine	Truvada
zidovudine, azidothymidine, AZT, ZDV	Retrovir
<b>NNRTIs</b>	
delavirdine, DLV	Rescriptor
efavirenz, EFV	Sustiva
etravirine	Intencele
nevirapine, NVP	Viramune
rilpivirine	Edurant
<b>Protease Inhibitors</b>	
amprenavir, APV	Agenerase <sup>1</sup>
atazanavir sulfate, ATV	Reyataz
darunavir	Prezista
fosamprenavir calcium, FOS-APV	Lexiva
indinavir, IDV	Crixivan
lopinavir and ritonavir, LPV/RTV	Kaletra
nelfinavir mesylate, NFV	Viracept
ritonavir, RTV	Norvir
saquinavir mesylate, SQV	Invirase
tipranavir, TPV	Aptivus

FDA-Approved Antiretroviral Medications (Continued)	
Generic Name	Brand Name
<b>Protease Inhibitor and CYP34A Inhibitor (Pharmacokinetic Booster) Combinations</b>	
atazanavir, cobicistat	Evotaz
darunavir/cobicistat	Prezcobix
<b>Fusion Inhibitors</b>	
enfuvirtide, T-20	Fuzeon
<b>Entry Inhibitors - CCR5 Co-Receptor Antagonist</b>	
maraviroc	Selzentry
<b>HIV Integrase Strand Transfer Inhibitors</b>	
dolutegravir	Tivicay
elvitegravir	Vitekta
raltegravir	Isentress

<sup>1</sup> The manufacturer of Agenerase (amprenavir) discontinued the sale and distribution of the drug in capsule form, used for adult dosing, after 2004 and is instead manufacturing fosamprenavir (Lexiva), a "prodrug" of Agenerase (a prodrug is an inactive precursor of a drug, converted into its active form in the body). Agenerase is still available in pediatric dosing.

Source: FDA, "Drugs Used in the Treatment of HIV Infection" Also see: DHHS, "Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents," December 16, 2013:

## APPENDIX 1

# HIV Antiretroviral and Opportunistic Infection Medications

"A1" Medications for the Prevention & Treatment of Opportunistic Infections (Highly Recommended) <sup>1</sup>	
Generic Name	Brand Name
acyclovir	Zovirax
amphotericin B deoxycholate	Fungizone
azithromycin	Zithromax
clarithromycin	Biaxin
clindamycin	Cleocin
ethambutol	Myambutol
famciclovir	Famvir
fluconazole	Diflucan
flucytosine	Ancobon
foscarnet	Foscavir
ganciclovir	Cytovene
isoniazid, INH	Lanizid, Nidrazid
itraconazole	Sporonox
liposomal amphotericin B	AmBisome
metronidazole	Flagyl, MetroCream, Metrogel, MetroLotion, Noritate, Rosadan
nitazoxanide	Alinia
pentamidine	Nebupent
prednisone	Deltasone, Liquid Pred, Metocorten, Orasone, Panasol, Prednicen-M, Sterapred
primaquine	–
pyrazinamide, PZA	Rifater
pyrimethamine	Daraprim
rifabutin	Mycobutin
rifampin, RIF	Rifadin, Rimactane
sulfadiazine, oral generic	Microsulfon
trimethoprim-sulfamethoxazole, TMP/SMX	Bactrim, Septra
valacyclovir	Valtrex
valganciclovir	Valcyte

<sup>1</sup> "A" = "should always be offered"; "1" = "evidence from at least one properly randomized, controlled trial"

Hepatitis C (HCV) Treatment Medications	
Generic Name	Brand Name
consensus interferon or interferon alfacon-1	Infergen
daclatasvir	Daklinza
dasabuvir, ombitasvir, paritaprevir, ritonavir	Viekira Pak XR <sup>1</sup>
elbasvir and grazoprevir	Zepatier
glecaprevir, pibrentasvir	Mavyret <sup>2</sup>
interferon alfa-2b	Intron A
interferon alfa-2b and ribavirin	Intron A, Rebetol
ledipasvir and sofosbuvir	Harvoni
ombitasvir, paritaprevir, and ritonavir	Technivie <sup>1</sup>
peginterferon alfa-2a	Pegasys
peginterferon alfa-2b	PEG-Intron
peginterferon alfa-2a + ribavirin	Pegasys, Copegus
peginterferon alfa-2b and ribavirin	PEG-Intron, Rebetol
recombinant interferon alfa-2a	Roferon
recombinant interferon alfa-2a and ribavirin	Roferon
simeprevir	Olysio <sup>3</sup>
sofosbuvir	Sovaldi
sofosbuvir, velpatasvir	Eplusa
sofosbuvir, velpatasvir, voxilaprevir	Vosevi <sup>4</sup>

<sup>1</sup> Viekira XR Pak and Technivie will no longer be produced as of January 1, 2019.

<sup>2</sup> Mavyret was approved by the FDA on August 3, 2017 and was thus only available during the latter half of the 2017 calendar year.

<sup>3</sup> Olysio was available during calendar year 2017, but was later discontinued and no longer produced as of May 25, 2018.

<sup>4</sup> Vosevi was approved by the FDA on July 18, 2017 and was thus only available during the latter half of the 2017 calendar year.

**Sources:** CDC, "Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus." MMWR, 51 (No. RR08), 1-46; 2002; CDC, "Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents." MMWR, 53 (No. RR15), 1-112; 2004. Also see: DHHS, "Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents," <http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf> December 16, 2013: